These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1439 related articles for article (PubMed ID: 8037844)

  • 1. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment.
    Safe SH
    Crit Rev Toxicol; 1994; 24(2):87-149. PubMed ID: 8037844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a neurotoxic equivalence scheme of relative potency for assessing the risk of PCB mixtures.
    Simon T; Britt JK; James RC
    Regul Toxicol Pharmacol; 2007 Jul; 48(2):148-70. PubMed ID: 17475378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicology, structure-function relationship, and human and environmental health impacts of polychlorinated biphenyls: progress and problems.
    Safe S
    Environ Health Perspect; 1993 Apr; 100():259-68. PubMed ID: 8354174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development validation and problems with the toxic equivalency factor approach for risk assessment of dioxins and related compounds.
    Safe SH
    J Anim Sci; 1998 Jan; 76(1):134-41. PubMed ID: 9464894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of the toxic equivalency factor approach for risk assessment of TCDD and related compounds.
    Safe S
    Teratog Carcinog Mutagen; 1997-1998; 17(4-5):285-304. PubMed ID: 9508738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impacts and impact mechanisms of "dioxins" in humans and animals].
    Nau H
    Dtsch Tierarztl Wochenschr; 2006 Aug; 113(8):292-7. PubMed ID: 16955640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), and related compounds: environmental and mechanistic considerations which support the development of toxic equivalency factors (TEFs).
    Safe S
    Crit Rev Toxicol; 1990; 21(1):51-88. PubMed ID: 2124811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinogenicity of "non-dioxinlike" polychlorinated biphenyls.
    Knerr S; Schrenk D
    Crit Rev Toxicol; 2006 Oct; 36(9):663-94. PubMed ID: 17050081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dioxin-like and non-dioxin-like toxic effects of polychlorinated biphenyls (PCBs): implications for risk assessment.
    Giesy JP; Kannan K; Blankenship AL; Jones PD; Hilscherova K
    Cent Eur J Public Health; 2000 Jul; 8 Suppl():43-5. PubMed ID: 10943457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessment of the carcinogenicity of polychlorinated biphenyls (PCBs).
    Smith MA
    J Toxicol Environ Health; 1997 Apr; 50(6):567-79. PubMed ID: 15279030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and assaying dioxin-like biological effects for both dioxin-like and certain non-dioxin-like compounds.
    Wilkes JG; Hass BS; Buzatu DA; Pence LM; Archer JC; Beger RD; Schnackenberg LK; Halbert MK; Jennings L; Kodell RL
    Toxicol Sci; 2008 Mar; 102(1):187-95. PubMed ID: 18065775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of TEFs for PCB congeners by using an alternative biomarker--thyroid hormone levels.
    Yang JM; Salmon AG; Marty MA
    Regul Toxicol Pharmacol; 2010 Mar; 56(2):225-36. PubMed ID: 20043972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive activity of polychlorinated biphenyl mixtures and congeners: nonadditive (antagonistic) interactions.
    Harper N; Connor K; Steinberg M; Safe S
    Fundam Appl Toxicol; 1995 Aug; 27(1):131-9. PubMed ID: 7589923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an oral cancer slope factor for Aroclor 1268.
    Warren DA; Kerger BD; Britt JK; James RC
    Regul Toxicol Pharmacol; 2004 Aug; 40(1):42-53. PubMed ID: 15265605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical effects of polychlorinated biphenyls: an overview and identification of research needs.
    Tilson HA; Kodavanti PR
    Neurotoxicology; 1997; 18(3):727-43. PubMed ID: 9339820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity equivalency factors for PCBs?
    Barnes D; Alford-Stevens A; Birnbaum L; Kutz FW; Wood W; Patton D
    Qual Assur; 1991 Oct; 1(1):70-81. PubMed ID: 1669971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polychlorinated biphenyls: correlation between in vivo and in vitro quantitative structure-activity relationships (QSARs).
    Leece B; Denomme MA; Towner R; Li SM; Safe S
    J Toxicol Environ Health; 1985; 16(3-4):379-88. PubMed ID: 3936939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs): biochemistry, toxicology, and mechanism of action.
    Safe S
    Crit Rev Toxicol; 1984; 13(4):319-95. PubMed ID: 6091997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the health effects of polychlorinated biphenyls (PCBs) and their metabolites using quantitative structure-activity relationship (QSAR).
    Ruiz P; Faroon O; Moudgal CJ; Hansen H; De Rosa CT; Mumtaz M
    Toxicol Lett; 2008 Sep; 181(1):53-65. PubMed ID: 18662755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.